Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre

Página do item simplificado
dc.creatorRosiana Estéfane da silva
dc.creatorAntonio Toledo Júnior
dc.creatorMaria Camilo Senna
dc.creatorAna Rabello
dc.creatorGlaucia Fernandes Cota
dc.date.accessioned2024-11-27T23:54:47Z
dc.date.accessioned2025-09-09T00:49:18Z
dc.date.available2024-11-27T23:54:47Z
dc.date.issued2016
dc.format.mimetypepdf
dc.identifier.doi10.1590/0074-02760160183
dc.identifier.issn1678-8060
dc.identifier.urihttps://hdl.handle.net/1843/78333
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofMemórias do Instituto Oswaldo Cruz
dc.rightsAcesso Aberto
dc.subjectLeishmaniose Cutânea
dc.subjectTerapia
dc.subjectAntimoniato de Meglumina
dc.titleIntralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre
dc.typeArtigo de periódico
local.citation.epage516
local.citation.issue8
local.citation.spage512
local.citation.volume111
local.description.resumoAlthough intralesional meglumine antimoniate (MA) infiltration is considered an option for cutaneous leishmaniasis (CL) therapy and is widely used in the Old World, there have been few studies supporting this therapeutic approach in the Americas. This study aims to describe outcomes and adverse events associated with intralesional therapy for CL. This retrospective study reviewed the experience of a Brazilian leishmaniasis reference centre using intralesional MA to treat 31 patients over five years (2008 and 2013). The median age was 63 years (22-86) and the median duration time of the lesions up to treatment was 16 weeks. In 22 patients (71%), intralesional therapy was indicated due to the presence of contraindications or previous serious adverse events with systemic MA. Other indications were failure of systemic therapy or ease of administration. Intralesional treatment consisted of one-six infiltrations (median three) for a period of up to 12 weeks. The initial (three months) and definitive (six months) cure rates were 70.9% and 67.7%, respectively. Most patients reported mild discomfort during infiltration and no serious adverse events were observed. In conclusion, these results show that the intralesional MA efficacy rate was very similar to that of systemic MA treatment, and reinforce the need for further studies with adequate design to establish the efficacy and safety of this therapeutic approach.
local.publisher.countryBrasil
local.publisher.departmentMEDICINA - FACULDADE DE MEDICINA
local.publisher.initialsUFMG
local.url.externahttps://www.scielo.br/j/mioc/a/hscMhJPD5TdhxkCvBdjgCvR/?lang=en#

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis- a retrospective review of a Brazilian referral centre.pdf
Tamanho:
244.94 KB
Formato:
Adobe Portable Document Format
Baixar

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG